Sanofi: Diabetes Mellitus, Type 2 trials
The registry lists 186 Diabetes Mellitus, Type 2 studies with Sanofi as lead sponsor. 1 are open to participants now and 46 have results posted.
Phase 1 16Phase 2 8Phase 3 80Phase 4 75No phase 7(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01689142Phase 3
- Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- MetforminCompletedNCT01632163Phase 3
- Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 DiabetesCompletedNCT01630369Phase 4
- Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 DiabetesCompletedNCT01572649Phase 1
- Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) FailureCompletedNCT01461577Phase 4
- Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes PatientsCompletedNCT01459809Phase 3
- Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With MetforminCompletedNCT01457911Phase 3
- Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin TherapyCompletedNCT01353469Phase 3
- Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination TreatmentCompletedNCT01336751Phase 3
- Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a DayCompletedNCT01234597Phase 4
- Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)CompletedNCT01212913Phase 4
- ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose CombinationCompletedNCT01204580Phase 4
- Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering DrugsCompletedNCT01203111Phase 4
- Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes MellitusCompletedNCT01169818Phase 4
- Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin AspartCompletedNCT01159353Phase 1
- Initiation and Titration of AmarylCompletedNCT01144728Phase 4
- Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 DiabetesCompletedNCT01127269Phase 4
- Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.CompletedNCT01122979Phase 4
- Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative StudyCompletedNCT01121835Phase 4
- Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral NutritionTerminatedNCT01081938Phase 4
- Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use SettingTerminatedNCT01079364Phase 4
- Observatory on Elderly Patients "Les S.AGES"CompletedNCT01065909
- Self Titration With Apidra to Reach Target Study (START)CompletedNCT01013571Phase 4
- Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsCompletedNCT00965549Phase 4
- Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes PatientsCompletedNCT00957060Phase 4
- Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary CareTerminatedNCT00950534Phase 4
- Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) TreatmentCompletedNCT00949442Phase 4
- Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes PatientsCompletedNCT00941369Phase 4
- Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2CompletedNCT00931372Phase 1
- Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of GlimepirideCompletedNCT00924573Phase 3
- Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)CompletedNCT00908921Phase 4
- Insulin Glargine Combination Therapies in Type II DiabeticsCompletedNCT00783744Phase 3
- Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 DiabetesWithdrawnNCT00754689Phase 3
- Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit ClinicsCompletedNCT00726674
- Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)CompletedNCT00708578Phase 4
- Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic ControlCompletedNCT00701831Phase 4
- Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed InsulinCompletedNCT00693771Phase 4
- Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 DiabetesTerminatedNCT00690456Phase 3
- Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)CompletedNCT00659477Phase 4
- Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)CompletedNCT00653341Phase 3
- Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)CompletedNCT00653302Phase 4
- Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)TerminatedNCT00627471Phase 4
- 20 Week Bridging Study in Type II DMCompletedNCT00563225Phase 3
- Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)CompletedNCT00562172Phase 4
- Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 DiabetesCompletedNCT00553020Phase 4
- Glycemic Optimization Treatment StudyCompletedNCT00552370Phase 4
- Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing AtenololCompletedNCT00549133Phase 4
- REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic AgentsCompletedNCT00546325Phase 3
- Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline GlargineCompletedNCT00518427Phase 4
- DOMME Dose Optimization Multicentric Mexican EvaluationCompletedNCT00488527Phase 4
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and ExerciseTerminatedNCT00478972Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic DrugTerminatedNCT00478595Phase 3
- Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk FactorsTerminatedNCT00458081Phase 3
- A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 DiabetesTerminatedNCT00449605Phase 3
- LAPAS Study: Insulin Glargine in Type 2 Diabetes MellitusCompletedNCT00423215
- Lantus Versus Levemir Treat-To-TargetCompletedNCT00405418Phase 4
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusCompletedNCT00399724Phase 4
- Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or MetforminCompletedNCT00384215Phase 4
- Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin TreatmentCompletedNCT00361738Phase 2
- Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination TherapyCompletedNCT00358124Phase 4
- Insulin Analogue With Continuous Glucose Monitoring System (CGMS) MeasurementCompletedNCT00354939Phase 4
- Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes MellitusCompletedNCT00353691Phase 3
- LANTUSTITR: Insulin Glargine in Type 2 Diabetes MellitusTerminatedNCT00349986Phase 4
- Insulin Glargine in Type 2 Diabetic PatientsCompletedNCT00347100Phase 4
- Lantus Effect on Myocardial Glucose Metabolism in T2CompletedNCT00335465Phase 4
- Insulin Glargine in Type 2 Diabetes MellitusCompletedNCT00311818Phase 4
- Insulin Glulisine in Type 2 Diabetes MellitusCompletedNCT00310297Phase 1
- Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes MellitusCompletedNCT00299871Phase 2
- Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes MellitusCompletedNCT00290927Phase 3
- Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)CompletedNCT00288236Phase 3
- Insulin Glargine in Type 2 Diabetes MellitusCompletedNCT00272077Phase 4
- ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.CompletedNCT00272064Phase 3
- OPAL - Insulin Glulisine, Diabetes MellitusCompletedNCT00272012Phase 3
- Insulin Glargine in Type 2 DiabetesCompletedNCT00268645Phase 4
- Insulin Glargine During and After the Period of Fasting in RamadanCompletedNCT00258804Phase 4
- Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic PatientsCompletedNCT00257257Phase 3
- Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic PatientsCompletedNCT00174824Phase 4
- Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 DiabetesCompletedNCT00174681Phase 4
- Insulin Glulisine in Diabetes Mellitus, Type 2CompletedNCT00174668Phase 3
- Opposing Step-by-step Insulin Reinforcement to Intensified StrategyCompletedNCT00174642Phase 3
- Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)CompletedNCT00135941Phase 3
- Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal InsulinCompletedNCT00135096Phase 3
- Variable Bolus Regimen 1-2-3 for Type 2 Diabetes MellitusCompletedNCT00135083Phase 3
- Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal InsulinCompletedNCT00135057Phase 3
- Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & ThiazolidinedioneCompletedNCT00044447Phase 3
- Obese Patients With Type 2 DiabetesCompletedNCT00029848Phase 3